Our commitment to patients and research

More than 50 million people worldwide currently live with dementia. This number is projected to reach 152 million by 2050, presenting society with a considerable healthcare challenge.

Alzheimer's disease is the most common form of dementia, accounting for 60-70% of all cases. It causes a decline in memory, reasoning and the ability to perform routine daily activities. The exact cause of the disease is not yet fully understood, and while treatments are available to alleviate its symptoms, there is currently no cure. 

Beyond the devastating impact on those living with Alzheimer's disease, it can cause profound emotional, physical and financial strain on families and caregivers. Grifols is committed to supporting those affected and as part of its mission has invested over €150 million in Alzheimer's research since 2004.

Grifols' integrated Alzheimer's approach for this neurodegenerative disease includes exploring the potential of plasma therapies to slow its advance. The pioneering AMBAR® (Alzheimer Management by Albumin Replacement) clinical program, based on periodic plasma exchange with albumin, is proven to delay cognitive and functional disease progression in mild-to-moderate Alzheimer's patients. 

In addition, Grifols is exploring new lines of Alzheimer's research through our subsidiaries Alkahest and Araclon.  

AMBAR® Procedure

AMBAR® entails a multimodal approach to the management of Alzheimer's. On one hand, periodic plasma exchange eliminates beta-amyloid protein, so that it does not accumulate in the brain and cause neuronal damage. On the other, the albumin administered may have other beneficial effects due to its antioxidant and anti-inflammatory properties, helping to slow the progression of the disease.